A
AMGN
AMGNReviewed16 segments tracked|5 years of data|Annual (10-K)
Total Revenue
$28.1B21.7%
FY2024
Operating Segments
16Active segments
Blended Margin
0.0%Operating margin
Highest Margin
0.0%Prolia
Segment Shift
Prolia has grown from 16.7% to 15.6% of total revenue since FY2020, with 0.0% operating margins. Meanwhile, KRYSTEXXA is the fastest growing at +335.7% YoY.
Segment Revenue Over Time
Revenue Mix
Segment Breakdown — FY2024
| Segment | Revenue | Op. Income | Margin | % of Total | YoY |
|---|---|---|---|---|---|
| Prolia | $4.4B | $0 | 0.0% | 15.6% | +8.1% |
| Enbrel | $3.3B | $0 | 0.0% | 11.8% | -10.3% |
| Xgeva | $2.2B | $0 | 0.0% | 7.9% | +5.4% |
| Repathaevolocumab | $2.2B | $0 | 0.0% | 7.9% | +35.9% |
| Otezla | $2.1B | $0 | 0.0% | 7.6% | -2.8% |
| TEPEZZA | $1.9B | $0 | 0.0% | 6.6% | +313.2% |
| EVENITY | $1.6B | $0 | 0.0% | 5.6% | +34.7% |
| Kyprolis | $1.5B | $0 | 0.0% | 5.4% | +7.1% |
| Nplate | $1.5B | $0 | 0.0% | 5.2% | -1.4% |
| Product And Service Other | $1.4B | $0 | 0.0% | 5.0% | +9.2% |
| Aranesp | $1.3B | $0 | 0.0% | 4.8% | -1.5% |
| BLINCYTO | $1.2B | $0 | 0.0% | 4.3% | +41.2% |
| KRYSTEXXA | $1.2B | $0 | 0.0% | 4.2% | +335.7% |
| Vectibix | $1.0B | $0 | 0.0% | 3.7% | +6.2% |
| TEZSPIRE | $972M | $0 | 0.0% | 3.5% | +0.0% |
| Bei Gene | $259M | $0 | 0.0% | 0.9% | +107.2% |
Want more? Unlock the full analysis.
Sign up free to access quarterly data, financial statements, trend analysis, geographic segments, Excel exports, and cross-company comparisons.
Get Started Free